In a 6-week human study Bonexid
produced statistically significant increases in indicators of bone formation and retention of calcium in bone, as well as decreases in markers of bone breakdown.
was studied in a prospective, double-blind, randomized, placebo-controlled human clinical trial performed by independent third party investigators who specialize in the supervision of this type of human experimentation. The study was conducted under the direction of an Institutional Review Board (IRB) that assures volunteers are safely treated. The test results were then published in a peer-reviewed medical journal.
The link to the Bonexid
published paper can be found: Here
- Patent (GB 2453797, AU 2006227949)
Composition and Method for Modulating Hydrogen Ion Physiology
patents cover a nutritional combination of ingredients designed to beneficially influence the physiologic pathways that regulate bone formation and bone breakdown.
By modulating the exact balance between these pathways, the innovative approach utilized in Bonexid
enables the body to better retain calcium and more effectively use calcium in the maintenance of strong, healthy bones.
Hydrogen ion concentration (pH) and cyclooxygenase enzyme function are beneficially regulated to act in a synergistic fashion to markedly enhance efficacy. When tested in humans, a beneficial impact on bone health with the use of Bonexid was detected in weeks.